4527 — Rohto Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥541bn
- ¥529bn
- ¥271bn
- 82
- 39
- 16
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.64 | ||
| PEG Ratio (f) | 2.02 | ||
| EPS Growth (f) | 8.39% | ||
| Dividend Yield (f) | 1.58% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.09 | ||
| Price to Tang. Book | 2.66 | ||
| Price to Free Cashflow | 18.23 | ||
| Price to Sales | 1.81 | ||
| EV to EBITDA | 11.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.1% | ||
| Return on Equity | 11.93% | ||
| Operating Margin | 12.17% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 188,327 | 181,287 | 199,646 | 238,664 | 270,840 | 313,526 | 351,693 | 8.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +54.58 | -1.2 | +25.36 | +24.43 | +15.52 | -1.17 | +8.39 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company principally engaged in the health and beauty care area. The Company primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The Company operates its business in domestic market and overseas markets, including Europe, Asia and America.
Directors
- Kunio Yamada CHM (65)
- Masashi Sugimoto PRE (60)
- Masaya Saito VPR (57)
- Shinichi Kunisaki MDR (65)
- Masako Rikiishi SEO (62)
- Hidetoshi Segi SEO (59)
- Tetsumasa Yamada SEO (72)
- Atsushi Hiyama DRC (55)
- Chiharu Takakura DRC (61)
- Akie Iriyama IND (49)
- Haruka Mera IND (33)
- Shingo Torii IND (68)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 15th, 1949
- Public Since
- October 2nd, 1961
- No. of Shareholders
- 32,079
- No. of Employees
- 7,259
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 228,138,738
- Address
- 1-8-1, Tatsumi-Nishi, Ikuno-ku, OSAKA-SHI, 544-8666
- Web
- https://www.rohto.co.jp/
- Phone
- +81 667581231
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4527
Rohto Pharmaceutical Co Ltd Annual Shareholders Meeting
Q1 2026 Rohto Pharmaceutical Co Ltd Earnings Release
Similar to 4527
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Rohto Pharmaceutical Co share price?
As of Today at 22:57 UTC, shares in Rohto Pharmaceutical Co are trading at ¥2,348. This share price information is delayed by 15 minutes.
How has the Rohto Pharmaceutical Co share price performed this year?
Shares in Rohto Pharmaceutical Co last closed at ¥2,348 and the price had moved by -20.75% over the past 365 days. In terms of relative price strength the Rohto Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -16.48% over the past year.
What are the analyst and broker recommendations for Rohto Pharmaceutical Co?
The overall consensus recommendation for Rohto Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rohto Pharmaceutical Co dividend yield?
The Rohto Pharmaceutical Co dividend yield is 1.32% based on the trailing twelve month period.
Does Rohto Pharmaceutical Co pay a dividend?
Last year, Rohto Pharmaceutical Co paid a total dividend of ¥31, and it currently has a trailing dividend yield of 1.32%.Looking ahead, the next dividend pay date is 2025-06-01.
When does Rohto Pharmaceutical Co next pay dividends?
We do not have data on when Rohto Pharmaceutical Co is to next pay dividends. The historic dividend yield on Rohto Pharmaceutical Co shares is currently 1.32%.
How do I buy Rohto Pharmaceutical Co shares?
To buy shares in Rohto Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rohto Pharmaceutical Co?
As of the previous close price of ¥2,348, shares in Rohto Pharmaceutical Co had a market capitalisation of ¥541bn.
Where are Rohto Pharmaceutical Co shares listed?
Here are the trading details for Rohto Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4527
What kind of share is Rohto Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Rohto Pharmaceutical Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rohto Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Rohto Pharmaceutical Co is ¥3,126. That is 33.17% above the last closing price of ¥2,348.
Analysts covering Rohto Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥139 for the next financial year.
Find out moreWhat is the trend in the Rohto Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rohto Pharmaceutical Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -23.2%.
As of the last closing price of ¥2,348, shares in Rohto Pharmaceutical Co were trading -20.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rohto Pharmaceutical Co PE Ratio?
The Rohto Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 15.64. The shares last closed at ¥2,348.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rohto Pharmaceutical Co?
Rohto Pharmaceutical Co's management team is headed by:
- Kunio Yamada - CHM
- Masashi Sugimoto - PRE
- Masaya Saito - VPR
- Shinichi Kunisaki - MDR
- Masako Rikiishi - SEO
- Hidetoshi Segi - SEO
- Tetsumasa Yamada - SEO
- Atsushi Hiyama - DRC
- Chiharu Takakura - DRC
- Akie Iriyama - IND
- Haruka Mera - IND
- Shingo Torii - IND